ViroLogic Announces New Jersey Medicaid Initiates Policy Covering HIV Drug Resistance Tests
November 17 2003 - 6:30AM
PR Newswire (US)
ViroLogic Announces New Jersey Medicaid Initiates Policy Covering
HIV Drug Resistance Tests 48 States and the District of Columbia
Medicaid Programs Now Reimburse for Resistance Testing SOUTH SAN
FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- ViroLogic,
Inc. today announced that the New Jersey Medicaid Program has
initiated a benefit coverage policy for phenotypic and genotypic
HIV drug resistance testing, effective November 1, 2003. New Jersey
joins 47 other states and the District of Columbia to implement
Medicaid policies enabling reimbursement of the Company's HIV drug
resistance assays. New Jersey has the fifth highest incidence of
cumulative reported AIDS cases. This includes the highest
percentage of women reported with AIDS and the third highest number
of reported pediatric AIDS cases. Medicaid is the single largest
payer for these patient populations. "Drug resistance threatens the
recent gains made in treating HIV infection. HIV resistance testing
offers clinicians the ability to adjust patient treatment
accordingly. This new policy provides further validation of the
utility of our resistance tests to manage HIV infection and will
expand accessibility for many more patients who are likely to
benefit from this important technology," said Tien Bui, ViroLogic's
Vice President of Sales and Marketing. In addition to statewide
Medicaid coverage, Medicare and many private payers, including but
not limited to Aetna US Healthcare, BlueCross BlueShield, Humana
and United HealthCare provide reimbursement and benefit coverage
for ViroLogic's HIV drug resistance assays. Several key states and
the District of Columbia also provide funding for Ryan White Title
programs. Questions about HIV drug resistance testing and
reimbursement can be directed to ViroLogic's reimbursement hotline
at 1-87-PHENOAID (1-877-436-6243), or to
http://www.phenosense.com/. About ViroLogic ViroLogic is a
biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide
and improve treatment of serious viral diseases such as AIDS and
hepatitis. The company's products are designed to help doctors
optimize treatment regimens that lead to better patient outcomes
and reduced costs. ViroLogic's technology is also being used by
numerous biopharmaceutical companies to develop new and improved
anti-viral therapeutics and vaccines targeted at emerging
drug-resistant viruses. More information about the Company and its
technology can be found on its web site at
http://www.virologic.com/. Certain statements in this press release
are forward-looking. These forward-looking statements are subject
to risks and uncertainties and other factors, which may cause
actual results to differ materially from the anticipated results or
other expectations expressed in such forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risk that the Company's products for patient testing may not
continue to be accepted or that increased demand from physicians or
from drug development partners may not develop as anticipated, the
risk that ViroLogic may not continue to realize anticipated
benefits from its cost-cutting measures, the timing of
pharmaceutical company clinical trials, whether payors will
authorize reimbursement for its products, whether the FDA or any
other agency will decide to regulate ViroLogic's products or
services, whether the Company will encounter problems or delays in
automating its processes, whether ViroLogic successfully introduces
new products, whether others introduce competitive products,
whether intellectual property underlying the Company's PhenoSense
technology is adequate, whether licenses to third party technology
will be available, whether ViroLogic is able to build brand loyalty
and expand revenues, and whether ViroLogic will be able to raise
sufficient capital when required. For a discussion of other factors
that may cause ViroLogic's actual events to differ from those
projected, please refer to the Company's most recent annual report
on Form 10-K and quarterly reports on Form 10-Q, as well as other
subsequent filings with the Securities and Exchange Commission.
DATASOURCE: ViroLogic, Inc. CONTACT: Karen Wilson, CFO of
ViroLogic, +1-650-624-4164, or Web site: http://www.virologic.com/
Copyright
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Virologic (NASDAQ:VLGC)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Virologic (MM) (NASDAQ): 0 recent articles
More Virologic (MM) News Articles